Patent application number | Description | Published |
20080299587 | METHODS OF MEASURING INHIBITION OF PLATELET AGGREGATION BY THROMBIN RECEPTOR ANTAGONISTS - A method is provided for measuring inhibition of platelet aggregation by a thrombin receptor antagonist. First, a blood sample is obtained from a patient treated with a thrombin receptor antagonist. The blood sample is mixed in combination with particles including an immobilized GPIIb/IIIa receptor ligand and a thrombin receptor activator. The combination is then incubated under conditions suitable for agglutinating the particles, and platelet-mediated agglutination is assessed in the mixture. The absence of agglutination indicates that the patient has reduced ability to form platelet thrombi in response to the thrombin receptor antagonist treatment. Also provided is a kit for measuring inhibition of platelet aggregation by a thrombin receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, a thrombin receptor activator, an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation. | 12-04-2008 |
20100184084 | METHODS FOR MEASURING PLATELET REACTIVITY OF INDIVIDUALS TREATED WITH DRUG ELUTING STENTS - A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation. | 07-22-2010 |
20110065125 | CONTROLLED PLATELET ACTIVATION TO MONITOR THERAPY OF ADP ANTAGONISTS - A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi. | 03-17-2011 |
20110081657 | CONTROLLED PLATELET ACTIVATION TO MONITOR THERAPY OF ADP ANTAGONISTS - A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi. | 04-07-2011 |
20140234859 | CONTROLLED PLATELET ACTIVATION TO MONITOR THERAPY OF ADP ANTAGONISTS - A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi. | 08-21-2014 |
Patent application number | Description | Published |
20090061381 | Systems and methods for 3D previewing - Systems and methods are disclosed to preview a scan includes placing a three dimensional (3D) scanner probe near an object to be scanned; scanning a portion of the object to generate a 3D model of the scanned portion of the object; and displaying the 3D model of the portion as a live 3D preview of the 3D model, wherein the live 3D preview provides feedback on the probe's position and orientation relative to the object. | 03-05-2009 |
20090133260 | 3D dental shade matching and apparatus - Systems and methods are disclosed to fabricate a restorative prosthesis. The system includes a scanner to intra orally capture color and translucency information along with a three dimensional (3D) shape of the dentition being reconstructed. The system also includes a computer aided design (CAD) module to receive the color and translucency information and the 3D shape to render a color accurate representation of the prosthesis for review, wherein the color, translucency and surface information is combined in a single digital prescription which is electronically transferred to a laboratory or CAD/CAM system for fabrication. The system provides the capability for 3D shape, color and translucency characteristics of the final prosthesis to be measured and quantitatively compared to the prescribed requirements. | 05-28-2009 |
20140329204 | DURABLE COATING METHOD FOR ENHANCEMENT OF SURFACE SCANNING OF DENTITION - A method is provided for enhancing the results of an optical scan of the surface of an object such as human dentition in which the surface may be dry or wet. The method includes the step of applying a composition to the surface, wherein the composition includes a volatile component that rapidly evaporates resulting in the transformation of the residual composition to a durable, water insoluble, non sticky film on the surface, whether applied in a dry-field or in a wet-field environment. The composition generally includes an agent that improves the quality of the optical return signal to a 3D optical scanner. The method further includes the steps of scanning the surface having the film with an optical scanner and then, once scanning has been completed, using an organic solvent, such as a mouthwash containing alcohol, to remove the film from the object's surface. | 11-06-2014 |
Patent application number | Description | Published |
20090061381 | Systems and methods for 3D previewing - Systems and methods are disclosed to preview a scan includes placing a three dimensional (3D) scanner probe near an object to be scanned; scanning a portion of the object to generate a 3D model of the scanned portion of the object; and displaying the 3D model of the portion as a live 3D preview of the 3D model, wherein the live 3D preview provides feedback on the probe's position and orientation relative to the object. | 03-05-2009 |
20090133260 | 3D dental shade matching and apparatus - Systems and methods are disclosed to fabricate a restorative prosthesis. The system includes a scanner to intra orally capture color and translucency information along with a three dimensional (3D) shape of the dentition being reconstructed. The system also includes a computer aided design (CAD) module to receive the color and translucency information and the 3D shape to render a color accurate representation of the prosthesis for review, wherein the color, translucency and surface information is combined in a single digital prescription which is electronically transferred to a laboratory or CAD/CAM system for fabrication. The system provides the capability for 3D shape, color and translucency characteristics of the final prosthesis to be measured and quantitatively compared to the prescribed requirements. | 05-28-2009 |
20110171604 | Method for manufacturing and supply of dental prosthesis - Systems and methods are disclosed for manufacturing a dental restorative prosthesis by capturing 3D dental data from a patient; sending the 3D dental data to a laboratory for fabricating a restoration blank, the blank having material below a preparation area; receiving the restoration blank from the laboratory; determining a reduction area from the patient during an in office visit and fabricating the reduction area from the restoration blank to match the patient dentition. | 07-14-2011 |
20140329204 | DURABLE COATING METHOD FOR ENHANCEMENT OF SURFACE SCANNING OF DENTITION - A method is provided for enhancing the results of an optical scan of the surface of an object such as human dentition in which the surface may be dry or wet. The method includes the step of applying a composition to the surface, wherein the composition includes a volatile component that rapidly evaporates resulting in the transformation of the residual composition to a durable, water insoluble, non sticky film on the surface, whether applied in a dry-field or in a wet-field environment. The composition generally includes an agent that improves the quality of the optical return signal to a 3D optical scanner. The method further includes the steps of scanning the surface having the film with an optical scanner and then, once scanning has been completed, using an organic solvent, such as a mouthwash containing alcohol, to remove the film from the object's surface. | 11-06-2014 |
Patent application number | Description | Published |
20110063573 | RNFL MEASUREMENT ANALYSIS - One embodiment of the present invention accounts for individual anatomical variation when evaluating optical nerve fiber measurements. In one aspect, contextual information is used to compensate or correct measurement data. In another aspect, reference coordinates are remapped for improved comparison or visualization. In one embodiment of this latter aspect, the method uses measurements of nerve fiber capacity and maps of nerve fiber retinal service to improve sensitivity and specificity in eye function metrics. In one instance, we use the birefringence of nerve fibers to determine the orientation of the fibers within the RNFL. Orientation of the fibers about the ONH is indicative of the service provided by the fibers and is used to improve the interpretation of thickness measurements of the nerve fiber layer. Normalized nerve fiber measurements about the optic nerve head improve specificity and sensitivity as compared to the standard model. These improvements are a result of partitioning the normative database or modifying the measurement data prior to comparison. Statistics on normalized measurements of nerve fiber bundles also show improvements in specificity and sensitivity. | 03-17-2011 |
20130120757 | METHODS, SYSTEMS AND APPLICATIONS OF VARIABLE IMAGING DEPTH IN FOURIER DOMAIN OPTICAL COHERENCE TOMOGRAPHY - Systems, methods and applications for adjusting the imaging depth of a Fourier Domain optical coherence tomography system without impacting the axial resolution of the system are presented. One embodiment of the invention involves changing the sweep rate of a swept-source OCT system while maintaining the same data acquisition rate and spectral bandwidth of the source. Another embodiment involves changing the data acquisition rate of a SS-OCT system while maintaining the same sweep rate over the same spectral bandwidth. Several applications of variable imaging depth in the field of ophthalmic imaging are described. | 05-16-2013 |
20130218927 | METHOD FOR SCALING OPHTHALMIC IMAGING MEASUREMENTS TO REFLECT FUNCTIONAL DISABILITY RISK - Methods for relating ophthalmic structural measurements to ophthalmic function are presented. The central idea is that each value for a given structural measurement can be empirically associated with a certain likelihood of disability or reduced function by measuring relevant patient populations in which some subjects have those disabilities This method is intended as an aid to doctors who manage glaucoma, or for the study of glaucoma or glaucoma therapy in clinical trials. The method could also be used in other progressive diseases where more than one method is used to diagnose and manage disease, and it is desirable to use a structural method to predict the risk of further functional loss. | 08-22-2013 |
20130286354 | ASSESSMENT OF RETINAL DISRUPTION - Systems and methods for improving the assessment of disruption or abnormalities to retinal layers are presented. The disruptions are detected by analyzing at least one segmented boundary of optical coherence tomography data. Several different types of analysis can be used alone or in combination to make an assessment of the level of disruption to the particular boundary or layer defined by the boundary. The results can be presented as an end face image and quantified to report an amount of disruption. In one embodiment, a method for determining the disruption to the photoreceptor outer segment is described. | 10-31-2013 |
20130301008 | ANALYSIS AND VISUALIZATION OF OCT ANGIOGRAPHY DATA - Methods for analyzing and visualizing OCT angiography data are presented. In one embodiment, an automated method for identifying the foveal avascular zone in a two dimensional en face image generated from motion contrast data is presented. Several 3D visualization techniques are presented including one in which a particular vessel is selected in a motion contrast image and all connected vessels are highlighted. A further embodiment includes a stereoscopic visualization method. In addition, a variety of metrics for characterizing OCT angiography image data are described. | 11-14-2013 |
20140276025 | MULTIMODAL INTEGRATION OF OCULAR DATA ACQUISITION AND ANALYSIS - Regions-of-interest discovered from analyses of images obtained from one imaging modality can be further observed, analyzed, supplemented, and further analyzed by one or more additional imaging modalities and in an automated way. In addition, one or more pathologies identified from analyses of these regions-of-interest, and a metric of the likelihood of the presence of disease, and/or a metric of risk of disease progression can be derived therefrom. | 09-18-2014 |
20140307933 | METHODS TO REDUCE VARIANCE IN OCT ANALYSIS OF THE MACULA - Methods for analyzing optical coherence tomography (OCT) images of the macula to reduce variance and improve disease diagnosis are presented. One embodiment of the invention is directed towards selecting analysis locations and data segmentation techniques to take advantage of structural homogeneities. Another embodiment is directed towards reducing the variance in a collection of normative data by transforming the individual members of the database to correspond to a Standard Macula. Variations in foveal size are corrected by radial transformation. Variations in layer thickness are corrected by axial shifting. Diagnosis is performed by comparing OCT images from a patient to the improved normative database. | 10-16-2014 |